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Abstract. Objectives: (1) To compare blood pressure
(BP) readings with an automated arm cuﬀ oscillo-
metric device (AutoBP) to readings with a mercury
sphygmomanometer (HgBP) and (2) to evaluate the
impact on the prevalence of hypertension (HBP) in a
population-based survey. Methods: (1) In a conve-
nience sample (‘‘Comparison Study’’), we mea-
sured BP with both AutoBP (Visomat OZ2)
and HgBP and we modeled BP diﬀerence
(DBP = HgBP)AutoBP) with multiple regression
analysis. (2) Using DBP, we calculated HgBP in a
survey previously conducted in Dar es Salaam
(‘‘Population Survey’’) in which BP was measured
with the automatic device Visomat OZ2 and we
compared the prevalence of HBP (‡140/90 mmHg or
treatment). Results: In the Comparison Study (404
subjects aged 25–64), systolic/diastolic BP was higher
by 4.4/4.7 mmHg (SE: 0.4/0.3) with HgBP than
AutoBP. The prevalence of HBP was 42% with
HgBP and 36% with AutoBP (relative diﬀerence of
14%). DBP was associated with age, BP and arm
circumference. In the Population Survey (9.254 sub-
jects aged 25–64), the prevalence of HBP was 17%
with calculated HgBP and 14% with AutoBP (rela-
tive diﬀerence of 20%). Conclusion: A small system-
atic bias in BP readings between two diﬀerent devices
had large impact on hypertension prevalence esti-
mates. This suggests that automated devices used in
epidemiological studies should be validated with
particular care.
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Introduction
The auscultatory technique with a mercury sphyg-
momanometer has long been considered as a good
standard to measure blood pressure (BP) [1]. How-
ever, automated devices are used increasingly often in
clinical practice and in epidemiological studies be-
cause such devices prevent several observer-related
biases [2], operators need less training, and mea-
surement procedures can be better standardized [1,
3–6]. In addition, the use of mercury devices is
declining due to environmental reasons. Accordingly,
the use of ‘‘validated and aﬀordable’’ automated
devices in low resources setting has been advocated
by a WHO expert panel [7].
BP readings with automatic devices rely on built-in
electronic algorithms and several standard validation
protocols have been developed [8–11]. The reliability
of automated devices can vary diﬀerentially over the
range of various characteristics, such as BP or arm
circumference, as shown by us [12] and others [5,
13–15]. Hence, validation protocols recommend that
devices should be tested over a large range of BP [9,
11], in various age categories [9, 16], and on persons
with small, medium and large arm circumference [8,
16]. Current validation protocols are not particularly
stringent and may allow for signiﬁcant BP diﬀerences
between devices [17, 18]. While a small bias in BP
readings from a given device may have limited sig-
niﬁcance at an individual level, it may have large
impact when assessing the prevalence of hypertension
(HBP) in epidemiological studies [17, 19]. Biases in
BP readings may prevent valid comparison of HBP
estimates between and within populations and mis-
lead health planning.
In 1999, we assessed the prevalence of HBP in the
population of Dar es Salaam, Tanzania [20] using a
validated automated device [13]. We found a lower
prevalence of HBP than another population-based
survey that had used mercury sphygmomanometers
[21]. We were unable to objectively quantify whether
the diﬀerence could relate, at least in part, to the
types of devices used in the surveys as we did not use
a mercury device in our survey.
We subsequently conducted a study in an inde-
pendent sample of subjects to compare BP readings
between the automated device used in the survey and
a mercury sphygmomanometer. We analytically
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modeled the BP diﬀerence between the devices and
calculated BP based on a mercury sphygmomanom-
eter that would have been obtained in the population
survey and compared BP categories based on both
devices.
Methods
Comparison study
We compared BP readings with a standard mercury
sphygmomanometer to reading with a validated arm-
cuﬀ automated device (Visomat OZ2) [13] in a
convenience sample of apparently healthy adults
visiting relatives or working at a hospital in Dar
es Salaam. Four hundred and four subjects agreed
to participate (referred hereafter as ‘‘Comparison
Study’’).
BP was measured in the sitting position, after a rest
of at least 5 min, on the left arm, at 1-min intervals
and at 2-mmHg precision. Mid arm circumference
was measured at 0.5 cm precision and cuﬀ size was
selected accordingly. Three readings were obtained
with each device. Mercury and automated devices
were used alternatively and the order in which the
ﬁrst device was chosen was selected randomly to
avoid a systemic bias related to spontaneously
decreasing BP over repeated readings [22]. With the
mercury device, systolic and diastolic BP was mea-
sured at Korotkoﬀ phases I and V. Measurements
were conducted by trained clinical oﬃcers. Oﬃcers
who took mercury readings were blind to results with
the automated device, and inversely. The average of
the second and the third BP readings with each device
was used to deﬁne automated device BP (AutoBP)
and mercury sphygmomanometer BP (HgBP), res-
pectively. Diﬀerence in BP were calculated as
DBP = HgBP)AutoBP.
Population survey
Between November 1998 and August 1999, we con-
ducted a cross-sectional survey of cardiovascular risk
factors in all adults living in ﬁve branches of the
710.000 inhabitants municipality of Temeke in Dar es
Salaam, Tanzania (referred hereafter as ‘‘Population
Survey’’). Methods of the population survey, partic-
ipants characteristics and the distribution of BP and
other risk factors have been reported previously [20].
The survey included 9254 subjects aged 25–64.
In the population survey, BP was measured at the
participants household, on persons seated, after a
rest of at least 5 min, on the left arm. Mid arm cir-
cumference was measured at 0.5 cm precision and
cuﬀ-size was selected accordingly. BP was measured
with an arm-cuﬀ oscillometric automated device Vi-
somat OZ2 (same device as used in the Comparison
Study) [13]. Three BP readings were obtained at
1-min intervals. The average of the second and the
third BP readings was used for BP estimates.
For both the Comparison Study and the Popula-
tion Survey, subjects were free to participate and gave
informed consent. Both studies were approved by the
Tanzanian National Institute of Medical Research
and the Tanzanian Commission for Science and
Technology. Cut-oﬀ values for BP categories fol-
lowed usual categories [23] and hypertension (HBP)
was deﬁned as BP ‡ 140/90 mmHg or current anti-
hypertension treatment.
Statistical analysis
One way ANOVA and t-test were performed for
comparison between continuous variables. Bland–
Altman plots were generated and limits of agreements
between readings of systolic and diastolic BP with
both devices were calculated [24]. With data from the
Comparison Study, we generated separate multivar-
iate linear regression models to predict systolic and
diastolic DBP that included, as independent variables
age, sex, mid-arm circumference and BP level. In
these models, we used categorical values (dummy
variables) for the dependent continuous variables.
We used these multivariate parameters to calculate
HgBP of the participants to the Population Survey.
We then compared the prevalence of BP categories
based on AutoBP (measured) and HgBP (calculated)
in the Population Survey. Age-standardized preva-
lence was adjusted to the age distribution of the
world standard population proposed by the WHO
[25]. Analyses were performed with Stata 8.0.
Results
Characteristics of the participants to the Comparison
Study are presented in Table 1. Four hundred and
four subjects (201 men, 203 women) participated in
the study. Systolic and diastolic BP were higher with
HgBP than with AutoBP. For systolic BP, mean DBP
was 4.4 mmHg (standard error: 0.4) and limits of
agreement ranged from )13.4 to 22.2 mmHg. For
diastolic BP, mean DBP was 4.7 mmHg (0.3) and
limits of agreement ranged from )9.2 to 18.6 mmHg.
Comparing HgBP to AutoBP, the prevalence of HBP
(‡140/90 mmHg or treatment) was respectively
42.1% (95% CI: 37.2–47.1) and 36.1% (31.4–41.0), a
relative underestimation of 14%, with AutoBP vs.
HgBP.
Table 2 shows DBP across categories of selected
variables in the Comparison Study. Systolic DBP did
not diﬀer across sex and age categories but decreased
with increasing categories of mid-arm circumference.
Systolic DBP was lower for the BP category 140–159/
90–99 mmHg. Diastolic DBP did not diﬀer across sex
categories but decreased with increasing categories of
age, mid-arm circumference, and BP.
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Table 3 shows the multivariate predictors of DBP
in the Comparison Study. The direction and magni-
tude of the associations were similar to those found in
univariate analysis.
Based on the parameters from the multivariate
analysis to predict DBP (Table 3), we calculated
HgBP in the Population Survey, i.e. BP that would
have occurred if a mercury sphygmomanometer had
been used for measurement instead of the automatic
device. Table 4 shows that BP was substantially
higher when readings were based on the mercury
device as compared to the automatic device in all age
and sex categories in the Population Survey.
Table 5 shows that the prevalence of HBP
(BP ‡ 140/90 mmHg or treatment) was substantially
underestimated in the Population Survey based on
the automated device (measured) as compared to the
mercury device (calculated). Comparing HgBP to
AutoBP, the crude prevalence of HBP was 17.3%
(16.5–18.0) vs. 13.8% (13.1–14.5), i.e. an underesti-
mation of 20% with AutoBP vs. HgBP. The preva-
lence estimates were respectively 16.4% (15.4–17.4)
vs. 13.2% (12.3–14.0) in men and 18.6% (17.3–19.9)
vs. 14.9% (13.7–16.1) in women.
The prevalence of selected BP categories in the
Population Survey diﬀered markedly depending on
the type of device used for assessing BP (Figure 1). A
higher prevalence of the BP category<120/80 mmHg
was observed with the automated device. For the other
BP categories, lower proportions were observed with
the automated device, but the magnitude of the dif-
ference tended to decrease with higher BP categories.
Discussion
Our data indicate that the automated device mark-
edly underestimated BP, as compared to measure-
ments based on a mercury device. Consequently, in a
population-based survey, the prevalence of HBP was
underestimated by 20% with the automated device as
compared to the mercury device.
The BP estimates in the population survey adjusted
for the bias between the automatic and mercury de-
vices are likely to better reﬂect the true levels in the
population of Dar Es Salaam (assuming that the
mercury sphygmomanometer constitutes the stan-
dard for BP measurement). This claim is also indi-
rectly supported by the fact that the adjusted
estimates better correspond to the prevalence found
in another study in the same city in 1996 based on
measurements with a mercury sphygmomanometer
[21]. However, diﬀerence in the prevalence between
the two studies could also relate to the fact that BP
Table 2. Diﬀerence in blood pressure measured with the
mercury sphygmomanometer and the automated device
(DBP) across selected characteristics of the subjects in the
Comparison Study
N Systolic
DBP
(mmHg)
SE p Diastolic
DBP
(mmHg)
SE p
Sex
Men 201 5.0 0.6 4.7 0.5
Women 203 3.7 0.6 ns 4.7 0.5 ns
Age (years)
25–34 150 5.0 0.6 6.8 0.5
35–44 104 4.0 0.9 5.2 0.7
45–54 79 2.9 1.1 2.8 0.9
55–64 71 5.2 1.3 ns 1.8 0.7 ***
Mid arm circumference (cm)
<27 151 6.2 0.6 5.9 0.5
27–29 131 4.6 0.8 4.6 0.6
‡30 122 1.9 0.8 *** 3.3 0.7 **
Blood pressure category (mmHg)
<120/80 166 6.8 0.5 8.0 0.4
120–139/80–89 106 3.6 0.8 4.8 0.6
140–159/90–99 67 0.3 1.2 2.0 0.8
‡160/100 65 3.5 1.4 *** )1.0 0.9 ***
Mean and standard error (SE).
BP category based on BP readings with the automated
device.
DBP, diﬀerence in blood pressure with the mercury
sphygmomanometer and with the automated device.
**p<0.01; ***p<0.001 for diﬀerence in DBP between
categories.
Table 1. Characteristics of the participants to the Comparison Study
Men (N = 201) SD Women (N = 203) SD
Age (years) 40.6 11.6 41.1 11.8
Body mass index (kg/m2) 24.0 5.4 25.6 4.1
Mid arm circumference (cm) 27.9 4.2 28.0 3.0
Systolic HgBP (mmHg) 133.5 25.4 129.7 24.4
Diastolic HgBP (mmHg) 87.1 15.6 85.8 14.6
Systolic AutoBP (mmHg) 128.5*** 24.8 126.0*** 25.2
Diastolic AutoBP (mmHg) 82.4*** 18.2 81.1*** 17.0
Mean and standard deviation (SD).
HgBP, blood pressure measured with the mercury sphygmomanometer.
AutoBP, blood pressure measured with the automated device.
***p < 0.001 comparing readings with either device.
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was based on the average of the second and third of
three BP readings in our survey versus the average of
the ﬁrst and second readings in the survey by
Edwards et al. [21].
In our comparison study, the arm circumference
and BP level were the main predictors of the diﬀer-
ence in BP (DBP). DBP was not related in a linear
manner but, instead, a diﬀerence was most apparent
for selected ranges of BP and arm circumference. This
is consistent with ﬁndings in several other studies that
DBP cannot be easily anticipated or predicted. In a
previously published validation study of the Visomat
OZ2 [13], systolic DBP was higher in hypertensive
compared to normotensive subjects, whereas diastolic
DBP was lower in hypertensive compared to normo-
tensive subjects. In a comparison study of an auto-
mated device with an aneroid sphygmomanometer,
Kroke et al. [5] found that systolic DBP was associ-
ated with lean body mass and age in both sex,
whereas diastolic DBP was associated with age in
Table 3. Association of the diﬀerence in blood pressure between devices (DBP) with selected characteristics in the Com-
parison Study
Systolic DBP (mmHg) Diastolic DBP (mmHg)
Regression
coeﬃcient
SE p Regression
coeﬃcient
SE p
Mid arm circumference (cm)
<27 0 – – 0 – –
27–29 )0.9 1.0 0.091 )1.2 0.7 ns
‡30 )2.8 1.1 0.001 )1.6 0.8 0.041
Age (years)
25–34 0 – – 0 – –
35–44 1.0 1.1 ns 0.6 0.8 ns
45–54 0.2 1.3 ns )1.0 0.9 ns
55–64 2.5 1.3 ns )2.3 0.9 0.016
Blood pressure category (mmHg)
<120/80 0 – – 0 – –
120–139/80–89 )3.1 1.1 0.006 )2.6 0.8 0.001
140–159/90–99 )6.3 1.3 0.000 )5.0 1.0 0.000
‡160/100 )3.5 1.3 0.009 )8.3 1.0 0.000
Constant 7.2 0.9 0.000 8.9 0.6 0.000
SE: standard error.
Blood pressure categories are based on the readings with the automated device.
DBP, diﬀerence in blood pressure with the mercury sphygmomanometer and with the automated device.
Table 4. Mean blood pressure (mmHg) by age, sex and type of device in the Population Survey
Age (years): 25–34 35–44 45–54 55–64 25–64 35–64*
Men
N 1930 910 481 279 3600 1670
Systolic
AutoBP 116.8 (0.3) 121.2 (0.6) 128.3 (0.9) 135.6 (1.4) 120.9 (0.3) 127.5 (0.6)
HgBP 121.5 (0.3) 126.0 (0.5) 131.6 (0.9) 140.9 (1.3) 125.5 (0.3) 131.9 (0.5)
Diastolic
AutoBP 71.2 (0.2) 75.8 (0.4) 80.5 (0.6) 82.3 (0.9) 74.5 (0.2) 79.2 (0.4)
HgBP 75.8 (0.2) 80.7 (0.4) 83.8 (0.6) 87.6 (0.8) 79.0 (0.2) 83.6 (0.3)
Women
N 3601 1191 540 322 5654 2053
Systolic
AutoBP 111.6 (0.2) 119.0 (0.5) 130.3 (1.0) 138.9 (1.4) 116.5 (0.3) 127.7 (0.6)
HgBP 116.8 (0.2) 124.0 (0.5) 133.5 (1.0) 144.0 (1.3) 121.5 (0.2) 132.2 (0.3)
Diastolic
AutoBP 69.2 (0.2) 74.5 (0.4) 79.9 (0.6) 81.5 (0.9) 72.0 (0.2) 78.0 (0.3)
HgBP 74.4 (0.2) 79.5 (0.3) 83.1 (0.6) 86.6 (0.8) 77.0 (0.2) 82.5 (0.3)
BP values are expressed as mean (and standard error).
AutoBP, BP measured with the automated device.
HgBP, BP corresponding to measurements with a mercury device calculated with parameters in Table 3.
*BP adjusted for age to the WHO world standard population [25].
430
men, and with upper arm circumference and BP level
in women. It was suggested that overestimation of BP
by a Dinamap oscillometric automated device could
relate to increased arterial stiﬀness [26], which is
typically found in elderly people. This bias is unlikely
to have occurred in our study as age, a major
determinant of arterial stiﬀness, was not associated
with systolic BP diﬀerence, at least up to age 64.
However, age tended to be associated with diastolic
BP diﬀerence.
The automated device that we used did satisfy the
validation criteria of the Association for the
46.7%
38.8%
10.2%
4.3%
29.6%
52.1%
13.6%
4.7%
60% 40% 20% 0% 20% 40% 60%
<120/80 mmHg
120-139/80-89 mmHg
140-159/90-99 mmHg
160/100 mmHg
AutoHg
MEN
59.5%
27.9%
7.9%
4.7%
42.8%
41.3%
10.9%
5.0%
60% 40% 20% 0% 20% 40% 60%
<120/80 mmHg
120-139/80-89 mmHg
140-159/90-99 mmHg
160/100 mmHg
AutoHg
 WOMEN
Figure 1. Prevalence of blood pressure categories based on readings with a mercury sphygmomanometer (HgBP; calculated)
or an automated device BP (AutoBP; measured); men and women aged 25–64 years, Dar es Salaam, Tanzania.
Table 5. Prevalence of hypertension (BP ‡ 140/90 mmHg and/or treatment) by sex, age and type of device in the Population
Survey
Age (year): 25–34 35–44 45–54 55–64 25–64 35–64*
Men
N 1930 910 481 279 3600 1670
AutoBP % 6.7 (0.6) 14.9 (1.2) 29.1 (2.1) 47.0 (3.0) 13.2 (0.4) 28.2 (1.2)
HgBP % 9.5 (0.7) 20.4 (1.3) 30.8 (2.1) 54.5 (3.0) 16.4 (0.5) 32.8 (1.2)
Women
N 3601 1191 540 322 5654 2053
AutoBP % 5.5 (0.4) 16.2 (1.1) 35.2 (2.1) 50.6 (2.8) 14.9 (0.6) 28.9 (1.1)
HgBP % 8.0 (0.5) 21.2 (1.2) 36.9 (2.1) 58.1 (2.8) 18.6 (0.6) 33.3 (1.1)
Prevalence (and standard error).
AutoBP, BP measured with the automated device.
HgBP, BP corresponding to measurements with a mercury device calculated with parameters in Table 3.
*BP adjusted for age to the WHO world standard population [25].
431
Advancement of Medical Instrumentation (AAMI)
protocol [8, 13] and, partly, those of the British
Hypertension Society (BHS) protocol [9, 13]. In the
validation study of this device [13], the mean
diﬀerence in BP between the automated device and
the mercury sphygmomanometer was 3.7±7.5/
4.8±5.6 mmHg, which is consistent with our
ﬁndings. The instrument used in our study is no
longer marketed and is not recommended by the
European Society of Hypertension [10]. However,
our ﬁndings are likely to have relevance for other
past, current, or future surveys of HBP that rely on
validated automated devices.
A small bias in epidemiological studies can lead to
large diﬀerences in the estimated prevalence of HBP
in a population. In a study comparing BP readings
with an aneroid device and readings with an auto-
mated device (BOSO Oscillomat), a systematic
diﬀerence as small as 0.2±5.6/0.5±3.5 mmHg led
to miss one male hypertensive case out of 12 (HBP
deﬁned as BP ‡160/95 mmHg) and one female case
out of 50 [5]. More recently, it was found that an
underestimation of systolic BP readings by 5 mmHg
could cause 21%–30% of patients with BP ‡140/
90 mmHg to be missed, whereas underestimation of
diastolic BP by 5 mmHg could cause respectively
47%–62% of hypertensive patients to be missed [19].
Based on the NHANES data, it was estimated that a
diﬀerence of 1 mmHg in BP would translate in a
prevalence change of 2% [Richard Cooper, personal
communication, May 2005]. Expectedly, the impact
will largely depend on the distribution of BP in the
population considered and will be greater if the
population mean BP is close to the cut-oﬀ for HBP
deﬁnition (e.g. 130–150/85–95 mmHg).
Systematic misclassiﬁcation of HBP will be limited
with clinically validated devices. However, current
validation protocols do not ensure that such prob-
lems cannot occur with adequately validated auto-
mated devices [27]. Some authors stated that current
validation protocols fail to ensure accuracy of auto-
mated devices [18, 27]. Indeed, several issues can be
raised. For example, a BP monitor that meets the
AAMI and BHS validation criteria may report BP in
error by more than 5 mmHg in more than 50% of the
participants to validation studies, and by more than
10 mmHg in more than 25% [17]. In addition, cur-
rent validation protocols require the participation of
a very low number of participants. Furthermore,
while there are some requirements concerning the
range of BP across which devices must be validated
[8, 9], such requirements have been relaxed in inter-
national protocol to encourage manufacturers to
submit BP automated device for validation [11].
While current validation protocols may possibly be
suﬃcient for devices intended to be used at an indi-
vidual level, a more stringent protocol might be con-
sidered for the validation of devices recommended for
epidemiological studies. Such recommendations could
include, for example, the need for a speciﬁed larger
minimal total sample of subjects included in validation
studies (e.g. ‡200); a speciﬁed minimal number of
persons with BP close to critical BP values for epide-
miology (e.g. ‡100 persons with BP of 130–150/85–
95 mmHg); a speciﬁed maximal overall tolerance in
measurements carried out in this critical BP range (e.g.
( £ 1 mmHg); and a speciﬁed minimal number of
persons with small, medium and large arms.
Pending more stringent validation protocols,
investigators using automated devices in epidemio-
logical studies could systematically validate auto-
mated devices within a subgroup of their study
participants. Also, manufacturers could systemati-
cally provide a Y connection with all automated de-
vices so that operators can easily compare BP
readings given by the automated device to readings
with a mercury device connected to the automated
device by means of the Y tube.
In conclusion, a small bias in BP readings between
diﬀerent types of sphygmomanometers can have a
large impact on hypertension prevalence estimates.
Automated devices used in epidemiological studies
should be validated with particular care, and possibly
with speciﬁc validation protocols. Comparison stud-
ies should be replicated in diﬀerent settings (e.g. other
populations) and under diﬀerent conditions (e.g.
other devices) to further characterize the bias that can
result from the use of diﬀerent devices.
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